KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Deffered Revenue: 2009-2023

Historic Non-Current Deffered Revenue for Alnylam Pharmaceuticals (ALNY) over the last 14 years, with Dec 2023 value amounting to $188.2 million.

  • Alnylam Pharmaceuticals' Non-Current Deffered Revenue fell 99.48% to $1.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.0 million, marking a year-over-year decrease of 99.48%. This contributed to the annual value of $188.2 million for FY2023, which is 2.90% down from last year.
  • As of FY2023, Alnylam Pharmaceuticals' Non-Current Deffered Revenue stood at $188.2 million, which was down 2.90% from $193.8 million recorded in FY2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' Non-Current Deffered Revenue peaked at $318.4 million during FY2019, and registered a low of $152.4 million during FY2021.
  • In the last 3 years, Alnylam Pharmaceuticals' Non-Current Deffered Revenue had a median value of $188.2 million in 2023 and averaged $178.1 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Non-Current Deffered Revenue spiked by 449.69% in 2019 and then slumped by 32.31% in 2021.
  • Alnylam Pharmaceuticals' Non-Current Deffered Revenue (Yearly) stood at $318.4 million in 2019, then decreased by 29.30% to $225.1 million in 2020, then crashed by 32.31% to $152.4 million in 2021, then rose by 27.19% to $193.8 million in 2022, then dropped by 2.90% to $188.2 million in 2023.